온라인 바카라사이트 steps up U.S. botulinum toxin expansion, eyes KRW 900 billion in sales by 2028

[by Ji, Yong Jun] Hugel has outlined a blueprint to reinforce its position as a leading representative of ‘K-Aesthetics’ in the United States, the world's largest market for botulinum toxin products. In this year marking the second anniversary of its U.S. market entry, the company is implementing a ‘hybrid sales model’ that combines a direct sales organization with continued distribution through partners. This strategy aims to simultaneously expand market penetration while improving overall profitability.

온라인 바카라사이트 participated in the Asia-Pacific (APAC) track presentation at the JP Morgan Healthcare Conference, held in San Francisco on January 15 (local time). As the world's largest healthcare investment forum, the conference serves as a platform for global pharmaceutical and biotechnology companies to present industry trends and management strategies.

During her presentation, Carrie Strom, Global CEO of Hugel, stated, "By leveraging our hybrid sales strategy alongside aggressive investment in the U.S. market, we aim to achieve annual revenue of KRW 900 billion (approximately USD 610.9 million) by 2028." She further emphasized that a core objective is to ‘generate more than 30% of total sales from the U.S. market.’

온라인 바카라사이트 appointed Strom as Global CEO in October 2025 as part of its strategy to accelerate expansion in the U.S. market. Prior to joining 온라인 바카라사이트, Strom served as Senior Vice President of AbbVie and held the role of Global President of Allergan Aesthetics for five years, from May 2020 to February of last year.

"The primary factor behind my decision to join Hugel was the strong competitiveness of Letybo, which has maintained an 'overwhelming No. 1' position in the Korean market. In overseas markets where the 'K-beauty' craze is gaining significant momentum, the title of being 'No. 1 in Korea' serves as a highly compelling marketing asset that builds trust and confidence among consumers," Strom remarked.

Strom identified 온라인 바카라사이트 of market share in the United States as her top initial priority. To this end, Strom has adopted a hybrid commercialization strategy. Following regulatory approval from the U.S. Food and Drug Administration (FDA) last year, the company entered the U.S. market through an early-stage partnership with its local partner, Benev. Letybo holds approximately 3% of the U.S. botulinum toxin market to date.

Hugel plans to establish its own direct sales organization in the U.S. by mid-year. "Given the nature of the U.S. market, key customers, including physicians and medical spas, tend to favor direct engagement with manufacturers. Accordingly, it is essential to maintain Benev's existing distribution network while simultaneously deploying Hugel's high-performing direct sales team to strategically target major accounts and key clinical sites," Strom explained.

This approach is expected to significantly enhance Hugel's profitability, as a rising proportion of sales generated through its proprietary sales organization is anticipated to drive profit margin increase. Strom outlined plans to increase the company’s U.S. market share to 10% by 2028 and 14% by 2030. In addition, Hugel aims to maintain its EBITDA margin of approximately 50% while simultaneously achieving revenue growth.

Daniel Chang, CEO of Hugel, plans to focus on the expansion of the company’s product portfolio by generating synergies with its existing flagship products, including botulinum toxin products and hyaluronic acid (HA) fillers. Within this year, the company aims to build a comprehensive aesthetics portfolio by actively pursuing strategic business development initiatives, such as technology licensing agreements and co-commercialization partnerships for ‘Skin Booster’ products.

At a press conference held on January 14 (local time) during the JP Morgan Healthcare Conference, Chang emphasized, "Maintaining the message of being 'No. 1 in K-Beauty' depends on securing strong market share, robust distribution capabilities, and product competitiveness in Korea." He added, "With a cosmetics lineup now in place alongside toxins and fillers, it is imperative to establish a portfolio capable of addressing the full spectrum of aesthetic needs."

"We will actively accelerate our transition into a truly global company by expanding our worldwide market share, with a particular focus on the United States. Building on our business performance, including portfolio optimization, we intend to drive aggressive sales growth. Above all, we will pursue company-wide efforts to maintain a sound financial structure, including the preservation of an industry-leading operating profit margin," Strom emphasized.